A conversation with International AIDS Society president Linda-Gail Bekker about a new report on what the future response to HIV should be, released at the the 22nd International AIDS Conference.
There are a number of measures determine adherence to PrEP, each with benefits and drawbacks. Currently, no one guideline or definitive standard is being used.
Leading researchers and clinicians who influence best practices for conversations about the direct and indirect impact of HIV infection and treatment agree that communications regarding transmission must shift.
At the recent Adherence 2018 Conference, Friedland emphasized the importance of engaging providers, as well as expanding the definition of HIV providers beyond the clinical setting to include social workers, HIV test counselors, and lawyers.
A panel at the 13th annual International Conference on HIV Treatment and Prevention Adherence discussed the ways in which violence complicates health outcomes for people with HIV.
Providers and researchers at the Adherence 2018 Conference discussed the role of data and surveillance through several approaches and how they are being used to understand local and global epidemics, marshal resources, and mobilize stakeholders for i...
Is Ending the HIV Epidemic Possible, and If So, How? IAPAC Meeting in Geneva Takes Stock of Progress and the Road Ahead
More than 200 health care providers, researchers, and advocates gathered in Geneva, Switzerland, from across the globe to discuss progress and challenges in turning the tide on the HIV epidemic across the globe at the "Controlling the Epidemic" Summi...
This year at CROI 2018 a few studies tried to explore possible mechanisms for the association of increased myocardial infarction risk and abacavir use.
M184V Mutation Associated With Increased Risk of Viral Blip but Not Viral Failure With 3TC-Based Dual Therapy
A retrospective analysis presented at CROI 2018 looked at risk of viral rebound in people who switched to lamivudine (Epivir, 3TC)-based dual antiretroviral therapy.
Efavirenz (Sustiva, Stocrin) alters hormone exposure from the vaginal ring in HIV positive women, similar or greater to that previously reported with oral hormonal contraceptives.